A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. - Wikidata - wikimedia - TriplyDB

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

http://www.wikidata.org/entity/Q33588432

about

HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis.New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010 The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signaling Protein chaperones: a composition of matter review (2008 - 2013).DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy Novel therapeutics for aggressive non-Hodgkin's lymphoma.Design, synthesis, and evaluation of small molecule Hsp90 probes.Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells.Recent progress in targeting cancer.Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.Ex vivo engineered immune organoids for controlled germinal center reactions.Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94 Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.The molecular biology of diffuse large B-cell lymphoma.Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

P2860

Q26778548-2925AF26-E8BE-4459-BCCC-AA012D8030C9 Q27022514-AE7A9089-A900-4E3F-82E2-3833CB0FFEBF Q27304386-E3727135-2FBD-4C06-B806-96ACE8DC1EC2 Q28485399-3C66A7AC-3AB1-4C02-B70C-282C7C5A3BE2 Q28539772-EE4D9F16-8E7E-4CD7-A9FA-2E2524B88D12 Q30374671-0AADC68C-44D7-43A2-BEA3-44F81C0EEFC5 Q31021133-C557C93F-9B9B-4F3B-A032-998E78994DFF Q33906881-BA152A4B-7B3D-4D8D-AD3D-87144FF6366F Q33992530-BB52F138-8C05-48A1-95BE-1B1DB6BA2FF2 Q34013266-245FB8AA-2B68-402C-AC11-4A4FB0CA8499 Q34096524-52647D1A-FB65-40E4-BAF1-0DA9190B29DF Q34162151-294C647F-F329-4415-8A96-5C4137AC1A64 Q34282588-CFB330C7-FE03-433C-BD70-55A94075E582 Q34360164-1A066A06-DB28-4795-877B-7F596EB1A8BE Q35111768-A7B44A14-505A-47AD-A2D8-935AFD9D47E1 Q35128528-459FF6BF-7856-40E9-810D-AF9A7E4AFEB6 Q35130674-BEA7984A-5067-49C2-A552-EC5CD27A8AF1 Q35510446-DE10A234-ECC0-4712-8CC0-1E111B881F43 Q35740782-6BC2A6F8-44EB-420B-9768-160760A8C3FF Q35760845-166579D4-3082-4086-B4FE-4214176AB5A3 Q35800838-19AF6E32-35FE-4648-97CC-2981779A4259 Q35812007-938A53AE-124A-4683-BDED-FCA173742984 Q35894216-C2E814B8-37CF-481D-9A27-70FE6FFF34C1 Q35899122-21A6B53F-FD5B-4901-973C-ED6A22CFAE3E Q36020841-429637EF-A440-4BA2-A638-31ECEC2B4884 Q36199628-12764318-8B9E-417C-8355-847B32529397 Q36217436-641AB0AE-EBA5-43D0-8FCB-CAC82A65C220 Q36335846-06C25301-A560-4D5F-A34F-359FD1A45FF0 Q36426254-9CE4F8B0-0209-4431-9339-682E4ACB9DA2 Q36596874-50EFB7B9-EAB6-4CCB-BB09-B12BD8E7B258 Q36612630-C523D386-0243-4625-95F3-059EF34C9E40 Q36654876-B0E25F0B-98FC-4F00-B5B6-5428D4C6AD47 Q36655158-A277C668-B335-4496-8F9E-DEAF058CA3DC Q37010253-5A4D277B-F47D-4748-945D-FAE9358E746D Q37164915-A3F5875B-9574-4ECD-A06F-633CBD5B2F34 Q37235682-E3060283-0121-46AB-B39B-2272F9A69879 Q37347239-CF86DBC4-2564-4B4E-AEF5-0FBE72AB63EB Q37475206-C32E1065-8B8C-461A-82F7-864E10536AC5 Q37638066-C4BD18AE-A969-40F8-9080-66C9BC6545F0 Q37695872-94717C06-20CB-428A-8E99-AF3CD1EEE427

P2860

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

http://www.wikidata.org/entity/Q33588432

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@ast

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@en

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@nl

type

label

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@ast

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@en

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@nl

prefLabel

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@ast

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@en

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@nl

P1433

Q33588432-6F003611-BA0A-4ACC-B54A-6F05E1F7543F

P1476

Q33588432-E0A22822-74DE-4A23-B6D2-ACC3DD219587

P2093

Q33588432-00B7A96E-767B-4F30-AA6F-A2A9F10A4D15

Q33588432-1B7B556C-D4CC-4938-8B8E-657789139444

Q33588432-2D0894EE-0E7E-406E-A271-4F7DFFFFD4EA

Q33588432-37880545-361B-40B6-9FBF-BEA782D7A538

Q33588432-44B6A681-E740-42C3-88D0-7F64BF55C794

Q33588432-4ACD39CA-9221-4CF5-A26F-6C7C8F12808C

Q33588432-4EC666FA-1004-4554-AB00-5C2E851D2D18

Q33588432-6628942A-D318-4F33-BAEE-A277C4D87F7C

Q33588432-A21801DB-8311-4CCA-9B45-8C9D7961D595

Q33588432-A717823B-FB42-4D0C-8AF7-1E84FE6268C7

P2860

Q33588432-0369D0DB-0483-48C8-9F7B-D6DDEC721712

Q33588432-06E6A88C-CFBF-4FC1-AB9D-6515CE6B9444

Q33588432-1080522B-156C-44D9-8974-28C2B543CB02

Q33588432-1EDABE37-A60F-49CC-85BA-DE950E489544

Q33588432-371D1DE3-1812-45CD-B330-CDF56AA6CEC5

Q33588432-45D3224B-C9A3-4703-9ABF-719B814A5A6D

Q33588432-4EA71CDE-C659-4B2D-A8E1-86F268E32F62

Q33588432-53B31C22-22EE-48BC-B060-08A2653A8863

Q33588432-5879BF9F-5F79-475D-8D6A-261692138E24

Q33588432-69B9F2BA-E951-454C-B9B6-1CFA9089DF77

P2888

Q33588432-4A526367-0526-41DA-9857-12B17927F944

P304

Q33588432-39B0E099-0F15-4343-9560-DBACEC0D4820

P31

Q33588432-37093283-52A7-4F5E-8690-0A4AE628ED3E

P356

Q33588432-89665315-334B-4A70-AAA5-B5D05E162B13

P407

Q33588432-8D98BEE5-5137-43D4-B670-9FC15C2766E4

P433

Q33588432-055BBCA8-8EE1-4D14-B843-BE828B5E99AB

P478

Q33588432-AC67A96D-92A5-43DC-8129-677078CA0BDA

P50

Q33588432-A2BC8835-9486-498F-A356-82B55C0CA6FE

Q33588432-B58E59D1-7B57-4A20-99F9-39991777CA10

P577

Q33588432-50E116FF-1CF2-4E7B-BE01-5C44F7F677C7

P5875

Q33588432-CC2B6EE2-8342-47A5-8906-8717AAF79B1C

P698

Q33588432-405A8BB8-2E29-4011-8096-EA7D2C75EB2D

P932

Q33588432-74B57540-0C57-4185-90D0-208C71E581A3

P356

P1433

Nature Medicine

P1476

A purine scaffold Hsp90 inhibi ...... -6-dependent B cell lymphomas.

@en

P2093

Alka Mallik

http://www.w3.org/2001/XMLSchema#string

Ana I Robles

http://www.w3.org/2001/XMLSchema#string

Ari Melnick

http://www.w3.org/2001/XMLSchema#string

Eloisi C Lopes

http://www.w3.org/2001/XMLSchema#string

Jennifer Walling

http://www.w3.org/2001/XMLSchema#string

Kapil N Bhalla

http://www.w3.org/2001/XMLSchema#string

Karen L Bunting

http://www.w3.org/2001/XMLSchema#string

Katerina Hatzi

http://www.w3.org/2001/XMLSchema#string

Lucas A Tsikitas

http://www.w3.org/2001/XMLSchema#string

Lyuba Varticovski

http://www.w3.org/2001/XMLSchema#string

P2860

Control of mRNA decay by heat shock-ubiquitin-proteasome pathway

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins

Modulation of Akt kinase activity by binding to Hsp90

Chaperone Hsp27, a novel subunit of AUF1 protein complexes, functions in AU-rich element-mediated mRNA decay

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamy

Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

Development of purine-scaffold small molecule inhibitors of Hsp90.

Hsp90: a chaperone for protein folding and gene regulation.

The Hsp90 chaperone machinery.

P2888

P304

1369-1376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2059

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Chiosis

Leandro Cerchietti

P577

2009-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40453730

http://www.w3.org/2001/XMLSchema#string

P698

19966776

http://www.w3.org/2001/XMLSchema#string

P932

2805915

http://www.w3.org/2001/XMLSchema#string